Our 3’UTR technology specifically targets and degrades any transcript of interest

Gallery

Contacts

411 University St, Seattle, USA

347-842-6873
339-368-0125
646-620-8700

The Engineered Drug 3′UTRMYC1-18 Degrades the c-MYC-STAT5A/B-PD-L1 Complex In Vivo to Inhibit Metastatic Triple-Negative Breast Cancer

  1. Awah CU*+, Glemaud Y, Levine F, Yang K, Ansary A, Dong F, Ash L, Zhang J, Ogunwobi OO+. Destabilized 3’UTR ARE therapeutically degrades ERBB2 in drug-resistant ERBB2+ cancer models. 2022; bioRxiv 2022.08.14.503914; doi: https://doi.org/10.1101/2022.08.14.503914

2. ChidiebereU.Awah*,Fu Dong,Fayola Levine, Leonard Ash,Yana Glemaud,Olorunseun Ogunwobi*. Engineered destabilized AU rich elements on the 3UTR of HER2 degrades HER2, inhibits proliferation, and induces apoptosis in HER2 positive trastuzumab resistant breast cancer cells. Cancer Res (2022) 82 (12_Supplement): 1788. https://doi.org/10.1158/1538-7445.AM2022-1788

3. Chidiebere Awah*,Fu Dong,Yana Glemaud,Fayola Levine,Olorunseun Ogunwobi*. Engineered destabilized ARE on the 3UTR of MYC degrades oncogenic c-MYC transcript and protein and induces apoptosis in multiple cancer type. Cancer Res (2022) 82 (12_Supplement): 1809. https://doi.org/10.1158/1538-7445.AM2022-1809

4. Awah CU*+, Ansary A, Glemaud Y, Levine F, Ogunwobi OO+. Effect of Engineered Destabilized HER2 3'UTR ARE on the Proliferation of HER2+ Trastuzumab Resistant Breast Cancer Cells 2022, SPEECH Conference

5. Awah CU*+, Glemaud Y, Ansary A,  Levine F, Ogunwobi OO+ Engineered Destabilized HER2 3'UTR ARE as Novel Therapeutics for EGFR T790M and HER2 mutated NSCLC, 2022, SPEECH Conference.

Nanocage delivered engineered destabilized HER2 3UTR ARE reduced growth of primary EGFR T790M HER2 overexpressing osimertinib and trastuzumab resistant non small cell lung cancer and inhibited liver and lung metastasis in vivo 

Chidiebere U. Awah; Joo Sun Mun; Baris Boylu; Alooka Paragodaarachchi; Chika Ochu; Junfei Zhang; Hiroshi Matsui; Olorunseun O. Ogunwobi. Cancer Res (2023) 83 (7_Supplement): 3417.
 
SaveTwitterLinkedInFacebook

In vivo inhibition of metastatic HER2 positive trastuzumab resistant breast cancer using engineered destabilized 3UTR ARE of HER2 improves survival outcomes

Chidiebere U. Awah; Joo Sun Mun; Baris Boylu; Alooka Paragodaarachchi; Chika Ochu; Junfei Zhang; Hiroshi Matsui; Olorunseun O. Ogunwobi. Cancer Res (2023) 83 (7_Supplement): 3900.

 
SaveTwitterLinkedInFacebook

Targeting cMYC in metastatic castration resistant and neuroendocrine prostate cancer

Chidiebere U. Awah; Olorunseun O. Ogunwobi. Cancer Res (2023) 83 (7_Supplement): 4504.

 
SaveTwitterLinkedInFacebook

Nanocage delivered engineered destabilized 3UTR ARE of cMYC inhibits triple negative breast cancer growth and metastasis in vivo by targeting cMYC and downregulating STAT5A5B

Chidiebere U. Awah; Joo Sun Mun; Baris Boylu; Alooka Paragodaarachchi; Chika Ochu; Junfei Zhang; Hiroshi Mastui; Olorunseun Ogunwobi. Cancer Res (2023) 83 (7_Supplement): 1459.

 
 
SaveTwitterLinkedInFacebook

Destabilized 3’UTR elements therapeutically degrade ERBB2 mRNA in drug-resistant ERBB2+ cancer models

Chidiebere U. Awah1,2*, Yana Glemaud1, Fayola Levine1,2, Kiseok Yang1, Afrin Ansary1, Fu Dong1, Leonard Ash1, Junfei Zhang3 and Olorunseun O. Ogunwobi1,2*